In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

"AstraZeneca plans major $3.5bn expansion drive in the US" was originally created and published by Investment Monitor, a ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Alliance revenues also included $49 million for Beyfortus. AstraZeneca records 50% share of gross profits on sales of ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

A: Pascal Soriot, CEO, explained that pharmaceuticals are typically not subject to import duties, and AstraZeneca sources its ...

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of ...

The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...

AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be implicated in the largest insurance fraud case ...